Principal Financial Group Inc. Has $25.23 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Principal Financial Group Inc. increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 40.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 258,495 shares of the medical equipment provider's stock after acquiring an additional 74,149 shares during the quarter. Principal Financial Group Inc. owned about 0.38% of Lantheus worth $25,229,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of LNTH. Avantax Advisory Services Inc. lifted its holdings in Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after purchasing an additional 132 shares in the last quarter. Foundry Partners LLC boosted its stake in Lantheus by 4.5% during the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after buying an additional 133 shares during the period. Moody National Bank Trust Division boosted its stake in Lantheus by 1.0% during the first quarter. Moody National Bank Trust Division now owns 14,910 shares of the medical equipment provider's stock worth $1,455,000 after buying an additional 141 shares during the period. Aurora Investment Counsel boosted its stake in shares of Lantheus by 0.8% during the fourth quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider's stock valued at $1,718,000 after purchasing an additional 146 shares during the period. Finally, Trueblood Wealth Management LLC boosted its stake in shares of Lantheus by 1.4% during the first quarter. Trueblood Wealth Management LLC now owns 11,037 shares of the medical equipment provider's stock valued at $1,077,000 after purchasing an additional 151 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 2.00% of the company's stock.

Lantheus Stock Up 1.3%

NASDAQ LNTH traded up $1.08 during trading on Wednesday, hitting $83.49. 733,761 shares of the company traded hands, compared to its average volume of 1,025,370. The company has a market capitalization of $5.78 billion, a P/E ratio of 23.72 and a beta of 0.12. The business has a fifty day simple moving average of $81.67 and a 200 day simple moving average of $90.11. Lantheus Holdings, Inc. has a 12 month low of $73.11 and a 12 month high of $126.89. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same period in the previous year, the business posted $1.69 EPS. The business's quarterly revenue was up .8% on a year-over-year basis. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. B. Riley reduced their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Finally, Truist Financial reduced their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $130.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.